صفحه 1 از جانب 34 نتایج
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to novel multibinding compounds (agents) that inhibit microsomal triglyceride transferase protein (MTP) and to pharmaceutical compositions comprising such compounds. Accordingly, the multibinding compounds and
FIELD OF THE INVENTION
The present invention relates to compounds which are inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion. These compounds can be useful for the prevention and treatment of various diseases, particularly atherosclerosis and its
FIELD OF THE INVENTION
The present invention relates to compounds which are inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion. These compounds can be useful for the prevention and treatment of various diseases, particularly atherosclerosis and its
BACKGROUND OF THE INVENTION
The present invention is directed toward bivalent ligands effective for blocking or inhibiting acyl-CoA: cholesterol O-acyltransferase enzyme (hereinafter, ACAT) which is a major regulator of cholesterol metabolism in cells. The blocking or inhibition of ACAT is useful in
BACKGROUND OF THE INVENTION
The present invention is directed toward bivalent ligands effective for blocking or inhibiting acyl-CoA; cholesterol O-acyltransferase enzyme (hereinafter, ACAT) which is a major regulator of cholesterol metabolism in cells. The blocking or inhibition of ACAT is useful in
BACKGROUND
1. Technical Field
This invention relates to methods and compositions for treating humans with hypertriglyceridemia using erythromycin compounds.
2. Background Information
Hypertriglyceridemia involves abnormally high concentrations of plasma triglycerides. Although an exact definition of
FIELD OF THE INVENTION
The present invention relates to compounds that are inhibitors of the microsomal triglyceride transfer protein. The invention also relates to methods of treatment of atherosclerosis, obesity, restenosis, coronary heart disease, hyperlipoproteinemia, hypercholesterolemia, and
FIELD OF INVENTION
The present invention relates to compounds and methods for regulating triglyceride levels.
BACKGROUND
One of the major causes of atherosclerosis and the related diseases, coronary heart disease (CHD), peripheral arterial disease (PAD), and cerebrovascular disease, is dyslipidemia.
FIELD
The invention relates generally to the fields of biochemistry, cell biology, molecular genetics, endocrinology, and cardiovascular medicine.
BACKGROUND
Contemporary Western type diets challenge lipid and glucose homeostasis by overloading blood with cholesterol, triglycerides, and glucose.
FIELD
The invention relates generally to the fields of biochemistry, cell biology, molecular genetics, endocrinology, and cardiovascular medicine.
BACKGROUND
Contemporary Western type diets challenge lipid and glucose homeostasis by overloading blood with cholesterol, triglycerides, and glucose.
FIELD
The invention relates generally to the fields of biochemistry, cell biology, molecular genetics, endocrinology, and cardiovascular medicine.
BACKGROUND
Contemporary Western type diets challenge lipid and glucose homeostasis by overloading blood with cholesterol, triglycerides, and glucose.
FIELD
The invention relates generally to the fields of biochemistry, cell biology, molecular genetics, endocrinology, and cardiovascular medicine.
BACKGROUND
Contemporary Western type diets challenge lipid and glucose homeostasis by overloading blood with cholesterol, triglycerides, and glucose.
BACKGROUND OF THIS MODEL
1. Subject Matter
This model relates to a novel hereditary postprandial hypertriglyceridemia rabbit, with normal serum triglyceride values under conditions of fasting and high levels of serum triglyceride, postprandially
2. Description of the Related Art
The three main
BACKGROUND
Obesity is a chronic disease that has reached global epidemic proportions with over 1 billion adults being overweight (BMI 25-29.9) or obese (BMI>30). In the U.S.A. alone, the number of adults who are either overweight or obese is estimated to be over 150 million and is still on the
BACKGROUND
Obesity is a chronic disease that has reached global epidemic proportions with over 1 billion adults being overweight (BMI 25-29.9) or obese (BMI>30). In the U.S.A. alone, the number of adults who are either overweight or obese is estimated to be over 150 million and is still on the